A pharmacy-prepared version of semaglutide that is not FDA-approved and not the same as Wegovy or Ozempic.
Compounded semaglutide is prepared by a licensed pharmacy, often as a vial requiring self-measured dosing. It is not FDA-approved, not reviewed for safety/effectiveness/quality before marketing, and not interchangeable with Wegovy or Ozempic. With the shortage resolved, lawful compounding is now narrow.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.